Home
Alivus Life Sciences Ltd Share Price History
Alivus Life Sciences Ltd
NSE : 12 Mar, 2025
1017.4532.8 (3.3%)
Prev Close
984.7
Open Price
994.0
Bid Price (QTY)
-
Offer Price (QTY)
-
Volume
67425
Today's High / Low
1043.8 / 980.0
52 WK High / Low
1335.1 / 676.5
Market Price of Alivus Life Sciences Ltd
1M
1Y
3Y
5Y
Monitoring Alivus Life Sciences Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.
History Market Price
| Date | Price | Open | High | Low |
|---|
Returns Comparison
1W
1M
3M
6M
1Y
3Y
5Y
10Y
Growth Parameters
| Parameter |  2018 |
|---|---|
| Sales (Cr.) | 0 |
| Sales YoY Gr. | - |
| Adj EPS | -434 |
| YoY Gr. | - |
| Net Profit (Cr.) | -0 |
| BVPS | -1398 |
Key Financial Parameters
| Parameter | 2018 |
|---|---|
| Return on Capital Emp. % | 0 |
| Op. Profit Mgn % | -4 |
| Net Profit Mgn % | -172 |
| Debt to Equity % | 0 |
Latest Shareholding
Promoters Holdings Over Time
About Alivus Life Sciences Ltd
- Glenmark Life Sciences Limited was incorporated as Zorg Laboratories Private Limited', on June 23, 2011 at Pune and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra at Pune.
- Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' dated 10 August 2018.
- A shareholders' resolution was passed on 13 August 2018 to convert the Company from a Private Limited Company to a Public Limited Company and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited.
- The Company acquired API Division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January, 2019.
Popular Search
FAQs for Alivus Life Sciences Ltd Share Price History
What are the key events that typically impact Alivus Life Sciences Ltd's share price history?
Key events that impact Alivus Life Sciences Ltd’s share price history include quarterly earnings releases, product launches, leadership changes, economic policies, and geopolitical developments.
How do stock splits affect Alivus Life Sciences Ltd's share price history?
Stock splits reduce the nominal price of Alivus Life Sciences Ltd's shares by increasing the number of outstanding shares, which typically makes the stock more accessible to a broader range of investors. Although the total market value of the company remains unchanged after the split, the split can affect investor perception and liquidity, potentially influencing the share price in the longer term.
How do dividends impact the share price history of Alivus Life Sciences Ltd?
Dividends can influence Alivus Life Sciences Ltd's share price history by typically causing a temporary dip on the ex-dividend date, as the stock price often adjusts to reflect the dividend payout. Over time, the impact of dividends on the share price may be offset by the company's overall financial performance and market conditions.
How do corporate announcements affect Alivus Life Sciences Ltd’s share price history?
Corporate announcements such as mergers, acquisitions, or strategic shifts can lead to significant price changes. Any optimistic development news on Alivus Life Sciences Ltd generally boosts the company’s share price, whereas negative news can lead to a decline in share price.
How can I use technical analysis to understand Alivus Life Sciences Ltd’s share price history?
To understand Alivus Life Sciences Ltd’s share price history using technical analysis, examine charts for patterns such as trends, support, and resistance levels, and apply indicators like moving averages or Relative Strength Index (RSI) to gauge potential future movements. Analyze historical data to identify recurring trends and signals that might suggest how the share price could behave under similar conditions.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
